Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
PR Newswire
SAN DIEGO, Aug. 19, 2026
SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws and breached fiduciary duties to shareholders.
Why Are We Investigating Sionna Therapeutics?
On Monday, August 10, 2026, Sionna Therapeutics stock plunged 92% to close at $4.51 after the Company reported disappointing results from its Phase 2a proof-of-concept study of SION-719 in cystic fibrosis.
According to media reports, the PreciSION CF trial failed to achieve its key activity endpoint, which measured the reduction in sweat chloride – a key marker of treatment success – when SION-719 was administered alongside the standard-of-care treatment Trikafta.
Though the Company finished the second quarter with "substantial financial resources," it intends to take measures to preserve capital while determining the appropriate path forward for its clinical pipeline.
What Can Shareholders Do Now?
If you lost money investing in Sionna Therapeutics contact Robbins LLP for more information by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP
A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.
To be notified if a class action against Sionna Therapeutics settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE Robbins LLP
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
United States